$MEIP
MEI Pharma, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023061976 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2023 Q2
Revenue $0.00 $65.30M $1.460M
YoY Change -100.0% 647.96% -87.21%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.018M $6.530M $9.970M
YoY Change -5.63% -12.77% 72.76%
% of Gross Profit
Research & Development $3.912M $3.485M $2.570M
YoY Change -74.45% -82.09% -88.23%
% of Gross Profit
Depreciation & Amortization $85.00K $87.00K $100.0K
YoY Change -7.61% -12.12% 17.65%
% of Gross Profit
Operating Expenses $3.912M $3.485M $12.54M
YoY Change -74.45% -82.09% -54.58%
Operating Profit -$11.93M $55.28M
YoY Change -233.65% -403.42%
Interest Expense $869.0K $1.090M $1.060M
YoY Change -34.71% -31.75% 662.59%
% of Operating Profit 1.97%
Other Income/Expense, Net $867.0K $1.093M -$10.00K
YoY Change -21775.0% -54750.0% 66.67%
Pretax Income -$11.06M $56.37M -$10.03M
YoY Change -207.9% -439.09% -37.56%
Income Tax
% Of Pretax Income
Net Earnings -$11.06M $56.37M -$10.03M
YoY Change -207.9% -439.11% -37.56%
Net Earnings / Revenue 86.33% -686.99%
Basic Earnings Per Share -$1.66 $8.46
Diluted Earnings Per Share -$1.66 $8.46 -$1.51
COMMON SHARES
Basic Shares Outstanding 6.663M 6.663M 6.663M
Diluted Shares Outstanding 6.663M 6.663M

Balance Sheet

Concept 2023 Q4 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $59.48M $82.20M $100.7M
YoY Change -52.1% -40.59% -34.29%
Cash & Equivalents $5.174M $3.372M $16.91M
Short-Term Investments $54.31M $78.80M $83.80M
Other Short-Term Assets $6.692M $6.200M $6.800M
YoY Change 87.56% 122.86% 77.55%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00 $0.00
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $66.17M $88.42M $107.5M
YoY Change -50.41% -40.62% -35.66%
LONG-TERM ASSETS
Property, Plant & Equipment $1.144M $1.229M $1.309M
YoY Change -21.43% -24.32% -21.14%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $12.37M $12.83M $13.28M
YoY Change -12.63% -12.59% 23.96%
TOTAL ASSETS
Total Short-Term Assets $66.17M $88.42M $107.5M
Total Long-Term Assets $12.37M $12.83M $13.28M
Total Assets $78.54M $101.3M $120.8M
YoY Change -46.79% -38.1% -32.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.378M $3.220M $6.134M
YoY Change -66.12% -61.75% -22.53%
Accrued Expenses $5.645M $4.289M $12.46M
YoY Change -60.65% -53.46% 15.17%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.038M $8.564M $20.34M
YoY Change -64.52% -63.46% -16.79%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $11.01M $11.30M $75.80M
YoY Change -85.62% -89.01% -24.94%
Total Long-Term Liabilities $11.01M $11.30M $75.80M
YoY Change -85.62% -89.01% -24.94%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.038M $8.564M $20.34M
Total Long-Term Liabilities $11.01M $11.30M $75.80M
Total Liabilities $19.05M $19.89M $96.19M
YoY Change -80.8% -84.25% -23.31%
SHAREHOLDERS EQUITY
Retained Earnings -$360.7M -$349.6M -$406.0M
YoY Change -5.2% -10.54% 8.5%
Common Stock $420.2M $431.0M $430.6M
YoY Change -2.04% 0.68% 0.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $59.49M $81.36M $24.62M
YoY Change
Total Liabilities & Shareholders Equity $78.54M $101.3M $120.8M
YoY Change -46.79% -38.1% -32.07%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$11.06M $56.37M -$10.03M
YoY Change -207.9% -439.11% -37.56%
Depreciation, Depletion And Amortization $85.00K $87.00K $100.0K
YoY Change -7.61% -12.12% 17.65%
Cash From Operating Activities -$11.06M -$18.49M -$11.30M
YoY Change -22.52% 25.09% -27.12%
INVESTING ACTIVITIES
Capital Expenditures $7.000K $0.00 $40.00K
YoY Change -100.0% -113.07%
Acquisitions
YoY Change
Other Investing Activities $24.52M $4.960M $19.44M
YoY Change 134.18% -64.05% -4.79%
Cash From Investing Activities $24.51M $4.957M $19.40M
YoY Change 132.71% -63.91% -3.54%
FINANCING ACTIVITIES
Cash Dividend Paid $11.70M
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -11.66M 0.000 0.000
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -11.06M -18.49M -11.30M
Cash From Investing Activities 24.51M 4.957M 19.40M
Cash From Financing Activities -11.66M 0.000 0.000
Net Change In Cash 1.798M -13.53M 8.100M
YoY Change -148.13% 1145.08% 75.02%
FREE CASH FLOW
Cash From Operating Activities -$11.06M -$18.49M -$11.30M
Capital Expenditures $7.000K $0.00 $40.00K
Free Cash Flow -$11.06M -$18.49M -$11.34M
YoY Change 24.56% -25.38%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2023Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001262104
CY2023Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q3 dei Amendment Flag
AmendmentFlag
false
CY2023Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q3 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2028-03-31
CY2023Q3 dei Document Type
DocumentType
10-Q
CY2023Q3 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q3 dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
CY2023Q3 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q3 dei Entity File Number
EntityFileNumber
001-41827
CY2023Q3 dei Entity Registrant Name
EntityRegistrantName
MEI Pharma, Inc.
CY2023Q3 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
51-0407811
CY2023Q3 dei Entity Address Address Line1
EntityAddressAddressLine1
11455 El Camino Real
CY2023Q3 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 250
CY2023Q3 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2023Q3 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q3 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
CY2023Q3 dei City Area Code
CityAreaCode
858
CY2023Q3 dei Local Phone Number
LocalPhoneNumber
369-7100
CY2023Q3 dei Security12b Title
Security12bTitle
Common Stock, $0.00000002 par value
CY2023Q3 dei Trading Symbol
TradingSymbol
MEIP
CY2023Q3 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q3 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q3 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q3 dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Bankruptcy Proceedings Reporting Current
EntityBankruptcyProceedingsReportingCurrent
true
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6662857
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3372000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16906000
CY2023Q3 us-gaap Short Term Investments
ShortTermInvestments
78830000
CY2023Q2 us-gaap Short Term Investments
ShortTermInvestments
83787000
CY2023Q3 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
0
CY2023Q2 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
85000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6220000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6750000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
88422000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
107528000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11600000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11972000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1229000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1309000
CY2023Q3 us-gaap Assets
Assets
101251000
CY2023Q2 us-gaap Assets
Assets
120809000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3220000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
6134000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4289000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12461000
CY2023Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2023Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
317000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1055000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1428000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8564000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
20340000
CY2023Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
0
CY2023Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
64545000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11326000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11300000
CY2023Q3 us-gaap Liabilities
Liabilities
19890000
CY2023Q2 us-gaap Liabilities
Liabilities
96185000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
226000000
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
226000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6663000
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6663000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6663000
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6663000
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
0
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
0
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
430984000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
430621000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-349623000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-405997000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
81361000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
24624000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
101251000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
120809000
CY2023Q3 us-gaap Revenues
Revenues
65297000
CY2022Q3 us-gaap Revenues
Revenues
8730000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3485000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19463000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6531000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7486000
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
10016000
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
26949000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
55281000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-18219000
CY2023Q3 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
0
CY2022Q3 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
1117000
CY2023Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
1094000
CY2022Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
480000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1093000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1595000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
56374000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-16624000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
8.46
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
8.46
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.49
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.49
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6663000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6663000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6663000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6663000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
24624000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
56374000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
363000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
81361000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14653000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
52413000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-16624000
CY2022Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-40000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1559000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
37308000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
56374000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-16624000
CY2023Q3 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
0
CY2022Q3 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
1117000
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
363000
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1559000
CY2023Q3 meip Non Cash Lease Expense
NonCashLeaseExpense
372000
CY2022Q3 meip Non Cash Lease Expense
NonCashLeaseExpense
349000
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
87000
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
99000
CY2023Q3 meip Increase Decrease In Unbilled Receivable
IncreaseDecreaseInUnbilledReceivable
-85000
CY2022Q3 meip Increase Decrease In Unbilled Receivable
IncreaseDecreaseInUnbilledReceivable
-2286000
CY2023Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-530000
CY2022Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1048000
CY2023Q3 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-2921000
CY2022Q3 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
500000
CY2023Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-8172000
CY2022Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1604000
CY2023Q3 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-64862000
CY2022Q3 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-971000
CY2023Q3 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-347000
CY2022Q3 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-307000
CY2023Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18491000
CY2022Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14782000
CY2023Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
CY2022Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
63000
CY2023Q3 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
24197000
CY2022Q3 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
34052000
CY2023Q3 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
29154000
CY2022Q3 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
47850000
CY2023Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4957000
CY2022Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13735000
CY2023Q3 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0
CY2022Q3 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
40000
CY2023Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
CY2022Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-40000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-13534000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1087000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16906000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15740000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3372000
CY2023Q3 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
7000
CY2022Q3 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
CY2023Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2022Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4347000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-349600000
CY2023Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
82200000
CY2023Q3 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the valuation of share-based awards, the discount rate used in estimating the present value of the right-of-use assets and lease liabilities, the useful lives of property and equipment, the recoverability of long-lived assets, clinical trial accruals, periods over which revenue should be recognized, relative stand-alone selling price, deferred income taxes and related valuation allowances, and the assessment of our ability to fund our operations for at least the next 12 months from the date of issuance of these condensed consolidated financial statements. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each reporting period and updated to reflect current information. As future events and their effects cannot be determined with precision, actual results may materially differ from those estimates or assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023Q3 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. Deposits in our checking and money market accounts are maintained in federally insured financial institutions and are subject to federally insured limits or limits set by the Securities Investor Protection Corporation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We attempt to minimize credit risk associated with our cash, cash equivalents and short-term investments by periodically evaluating the credit quality of our primary financial institutions. Our investment portfolio is maintained in accordance with our investment policy, which is designed to preserve capital, safeguard funds and limit exposure to risk. While we maintain cash deposits in Federal Deposit Insurance Corporation insured financial institutions in excess of federally insured limits, we do not believe that we are exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. We have not experienced any losses on such accounts.</span>
CY2023Q3 us-gaap Short Term Investments
ShortTermInvestments
78800000
CY2023Q2 us-gaap Short Term Investments
ShortTermInvestments
83800000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2023Q3 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
0
CY2023Q2 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
85000
CY2023Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
317000
CY2022Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
30900000
CY2023Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-317000
CY2023 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-5411000
CY2023Q3 us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
0
CY2023 us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
-16565000
CY2023Q3 meip Contract With Customer Liability Revenue Recognized Performance Obligations No Longer Commence
ContractWithCustomerLiabilityRevenueRecognizedPerformanceObligationsNoLongerCommence
0
CY2023 meip Contract With Customer Liability Revenue Recognized Performance Obligations No Longer Commence
ContractWithCustomerLiabilityRevenueRecognizedPerformanceObligationsNoLongerCommence
-8607000
CY2023Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0
CY2023Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
317000
CY2023Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0
CY2022Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1550000
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2192000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2350000
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2343000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1121000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1034000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1229000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1309000
CY2023Q3 meip Accrued Preclinical And Clinical Costs
AccruedPreclinicalAndClinicalCosts
730000
CY2023Q2 meip Accrued Preclinical And Clinical Costs
AccruedPreclinicalAndClinicalCosts
3663000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1515000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7189000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1044000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1423000
CY2023Q3 meip Accrued Reimbursement To Related Party
AccruedReimbursementToRelatedParty
892000
CY2023Q2 meip Accrued Reimbursement To Related Party
AccruedReimbursementToRelatedParty
0
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
108000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
186000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4289000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12461000
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2023Q3 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.51
CY2023Q3 us-gaap Lessor Operating Lease Option To Extend
LessorOperatingLeaseOptionToExtend
November 2029
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
584000
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
567000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1751000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1913000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2477000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2551000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2715000
CY2023Q3 meip Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
4385000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
15792000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3411000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
12381000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1055000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11326000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
12381000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y2M12D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.075
CY2022Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
0
CY2022Q3 meip Number Of Warrants Exercised
NumberOfWarrantsExercised
0
CY2023Q3 meip Number Of Warrants Exercised
NumberOfWarrantsExercised
0
CY2023Q3 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
226100000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
226000000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one vote per share
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
363000
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1559000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1284907
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
38.32
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
227037
CY2023Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.01
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
64817
CY2023Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
36.35
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1447127
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
33.50
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M6D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
789000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
819813
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
49.16
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y3M18D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3100000
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y7M6D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.046
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.028
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y8M12D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.898
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.841
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.27
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.8

Files In Submission

Name View Source Status
meip-20230930_lab.xml Edgar Link unprocessable
0000950170-23-061976-index-headers.html Edgar Link pending
0000950170-23-061976-index.html Edgar Link pending
0000950170-23-061976.txt Edgar Link pending
0000950170-23-061976-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img104063219_0.jpg Edgar Link pending
img104063219_1.jpg Edgar Link pending
img104063219_2.jpg Edgar Link pending
meip-20230930.htm Edgar Link pending
meip-20230930.xsd Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
meip-20230930_cal.xml Edgar Link unprocessable
meip-20230930_def.xml Edgar Link unprocessable
meip-20230930_htm.xml Edgar Link completed
meip-ex31_1.htm Edgar Link pending
meip-ex31_2.htm Edgar Link pending
meip-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
meip-20230930_pre.xml Edgar Link unprocessable
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending